Analysis of Time to Event Outcomes in Randomized Controlled Trials by Generalized Additive Models

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Apr 24

PMID 25906075

Citations 4

Authors

Christos Argyropoulos

Mark L Unruh

Affiliations

Soon will be listed here.

Abstract

Background: Randomized Controlled Trials almost invariably utilize the hazard ratio calculated with a Cox proportional hazard model as a treatment efficacy measure. Despite the widespread adoption of HRs, these provide a limited understanding of the treatment effect and may even provide a biased estimate when the assumption of proportional hazards in the Cox model is not verified by the trial data. Additional treatment effect measures on the survival probability or the time scale may be used to supplement HRs but a framework for the simultaneous generation of these measures is lacking.

Methods: By splitting follow-up time at the nodes of a Gauss Lobatto numerical quadrature rule, techniques for Poisson Generalized Additive Models (PGAM) can be adopted for flexible hazard modeling. Straightforward simulation post-estimation transforms PGAM estimates for the log hazard into estimates of the survival function. These in turn were used to calculate relative and absolute risks or even differences in restricted mean survival time between treatment arms. We illustrate our approach with extensive simulations and in two trials: IPASS (in which the proportionality of hazards was violated) and HEMO a long duration study conducted under evolving standards of care on a heterogeneous patient population.

Findings: PGAM can generate estimates of the survival function and the hazard ratio that are essentially identical to those obtained by Kaplan Meier curve analysis and the Cox model. PGAMs can simultaneously provide multiple measures of treatment efficacy after a single data pass. Furthermore, supported unadjusted (overall treatment effect) but also subgroup and adjusted analyses, while incorporating multiple time scales and accounting for non-proportional hazards in survival data.

Conclusions: By augmenting the HR conventionally reported, PGAMs have the potential to support the inferential goals of multiple stakeholders involved in the evaluation and appraisal of clinical trial results under proportional and non-proportional hazards.

Citing Articles

Plasmodium falciparum gametocyte carriage in longitudinally monitored incident infections is associated with duration of infection and human host factors.

Andolina C, Ramjith J, Rek J, Lanke K, Okoth J, Grignard L Sci Rep. 2023; 13(1):7072.

PMID: 37127688 PMC: 10150352. DOI: 10.1038/s41598-023-33657-3.

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.

Chaparro M, Baston-Rey I, Fernandez Salgado E, Gonzalez Garcia J, Ramos L, Palomares M J Clin Med. 2022; 11(15).

PMID: 35956133 PMC: 9369748. DOI: 10.3390/jcm11154518.

High performance implementation of the hierarchical likelihood for generalized linear mixed models: an application to estimate the potassium reference range in massive electronic health records datasets.

Bologa C, Pankratz V, Unruh M, Roumelioti M, Shah V, Shaffi S BMC Med Res Methodol. 2021; 21(1):151.

PMID: 34303362 PMC: 8310602. DOI: 10.1186/s12874-021-01318-6.

Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Argyropoulos C, Chen S, Ng Y, Roumelioti M, Shaffi K, Singh P Front Med (Lausanne). 2017; 4:73.

PMID: 28664159 PMC: 5471312. DOI: 10.3389/fmed.2017.00073.

References

Bauman K, Suchindran C, Murray D . The paucity of effects in community trials: is secular trend the culprit?. Prev Med. 1999; 28(4):426-9. DOI: 10.1006/pmed.1998.0447. View

Coulter A . Partnerships with patients: the pros and cons of shared clinical decision-making. J Health Serv Res Policy. 1997; 2(2):112-21. DOI: 10.1177/135581969700200209. View

Earle C, Pham B, Wells G . An assessment of methods to combine published survival curves. Med Decis Making. 2000; 20(1):104-11. DOI: 10.1177/0272989X0002000113. View

Greene T, Beck G, Gassman J, Gotch F, Kusek J, Levey A . Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials. 2000; 21(5):502-25. DOI: 10.1016/s0197-2456(00)00062-3. View

Clase C, St Pierre M, Churchill D . Conversion between bromcresol green- and bromcresol purple-measured albumin in renal disease. Nephrol Dial Transplant. 2001; 16(9):1925-9. DOI: 10.1093/ndt/16.9.1925. View

Ghali W, Quan H, Brant R, van Melle G, Norris C, Faris P . Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA. 2001; 286(12):1494-7. DOI: 10.1001/jama.286.12.1494. View

Chen P, Tsiatis A . Causal inference on the difference of the restricted mean lifetime between two groups. Biometrics. 2002; 57(4):1030-8. DOI: 10.1111/j.0006-341x.2001.01030.x. View

Case L, Kimmick G, Paskett E, Lohman K, Tucker R . Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002; 7(3):181-7. DOI: 10.1634/theoncologist.7-3-181. View

Pocock S, Assmann S, Enos L, Kasten L . Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002; 21(19):2917-30. DOI: 10.1002/sim.1296. View

10.

Eknoyan G, Beck G, Cheung A, Daugirdas J, Greene T, Kusek J . Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347(25):2010-9. DOI: 10.1056/NEJMoa021583. View

11.

Cai T, Betensky R . Hazard regression for interval-censored data with penalized spline. Biometrics. 2003; 59(3):570-9. DOI: 10.1111/1541-0420.00067. View

12.

Spruance S, Reid J, Grace M, Samore M . Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004; 48(8):2787-92. PMC: 478551. DOI: 10.1128/AAC.48.8.2787-2792.2004. View

13.

Bender R, Augustin T, Blettner M . Generating survival times to simulate Cox proportional hazards models. Stat Med. 2005; 24(11):1713-23. DOI: 10.1002/sim.2059. View

14.

Eberly L, Neaton J, Thomas A, Yu D . Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial. Clin Trials. 2005; 1(2):148-61. DOI: 10.1191/1740774504cn018oa. View

15.

Burton A, Altman D, Royston P, Holder R . The design of simulation studies in medical statistics. Stat Med. 2006; 25(24):4279-92. DOI: 10.1002/sim.2673. View

16.

Vonesh E, Snyder J, Foley R, Collins A . Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us?. Kidney Int Suppl. 2006; (103):S3-11. DOI: 10.1038/sj.ki.5001910. View

17.

Orsi C, Bartolozzi B, Messori A, Bosi A . Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant. 2007; 40(7):643-9. DOI: 10.1038/sj.bmt.1705790. View

18.

Zhang X, Loberiza F, Klein J, Zhang M . A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007; 88(2):95-101. DOI: 10.1016/j.cmpb.2007.07.010. View

19.

Tsiatis A, Davidian M, Zhang M, Lu X . Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med. 2007; 27(23):4658-77. PMC: 2562926. DOI: 10.1002/sim.3113. View

20.

Locatelli F, Gauly A, Czekalski S, Hannedouche T, Jacobson S, Loureiro A . The MPO Study: just a European HEMO Study or something very different?. Blood Purif. 2008; 26(1):100-4. DOI: 10.1159/000110574. View